Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Neuropsychopharmacology Reports · 2024
DOI: 10.1002/npr2.12382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Kyle Arsenault-Mehta und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Ottawa Mental Health Center, The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Schizophrenia, Cognitive Dysfunction, Cognition Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cognitive impairment are among the core features of schizophrenia, experienced by up to 75% of patients. Available treatment options for schizophrenia including dopamine antagonists and traditional antipsychotic medications have not been shown to confer significant benefits on cognitive deficits. Contrary to the focus on management of positive symptoms in schizophrenia, cognitive abilities are main predictor of independent living skills, functional abilities, employment, engagement in relapse prevention, and patients' subjective sense of well‐being and quality of life. This review aims to provide a summary of recent literature on pharmacological options for the treatment of cognitive deficits in schizophrenia.
Methods
We conducted a literature search of studies from 2011 to 2021 across four electronic databases including PubMed, PsycInfo, MEDLINE, and Embase. Human studies using a pharmacological treatment for cognitive impairment in schizophrenia were included.
Results
Fifty‐eight eligible publications, representing 11 pharmacological classes, were included in this review. Major limitations involved small sample size, methodological limitations as well as heterogeneity of participants and outcome measures.
Conclusions
Overall evidence remains inconclusive for any pharmacological classes studied for the treatment of cognitive deficits in schizophrenia. Methodological limitations in a majority of the studies rendered their findings preliminary. We further discuss possible explanations for these findings that could guide future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Royal Ottawa Mental Health Center, The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
- The University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
- Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Naista Zhand
Zitieren
APA
Arsenault-Mehta, K., Hochman-Bérard, M., Johnson, A., Semenova, D., Nguyen, B., Willis, J., Mouravska, N., Joober, R., & Zhand, N. (2024). Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12382
Vancouver
Arsenault-Mehta K, Hochman-Bérard M, Johnson A, Semenova D, Nguyen B, Willis J, et al. Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12382
BibTeX
@article{ArsenaultMehta2024,
author = {Arsenault-Mehta, Kyle and Hochman-Bérard, Mario and Johnson, Alexander and Semenova, Dar'ya and Nguyen, Bea and Willis, Jessie and Mouravska, Natalia and Joober, Ridha and Zhand, Naista},
title = {Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review},
journal = {Neuropsychopharmacology Reports},
year = {2024},
doi = {10.1002/npr2.12382}
}
EUVIMED